Clinical efficacy of different doses of rituximab in the treatment of pemphigus

A retrospective study of 27 patients

J. H. Kim, Y. H. Kim, M. R. Kim, SooChan Kim

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Summary Background The treatment of pemphigus is still challenging and some patients with pemphigus are unresponsive to conventional immunosuppressive treatments. Rituximab, a chimeric monoclonal anti-CD20 antibody, binds to the CD20 antigen on the surface of B cells and has been reported to be effective for the treatment of recalcitrant pemphigus. Objective To compare the efficacy of different doses of rituximab in patients with pemphigus who were unresponsive to conventional therapies. Methods Twenty-seven patients with pemphigus who received different doses of rituximab (375 mg m -2 per infusion weekly) were analysed retrospectively. We divided the patients into two groups: group 1 (n = 12) received two infusions of rituximab and group 2 (n = 15) received three or more infusions of rituximab at 1-week intervals. The number of infusions was determined by the choice of each patient. The endpoints of the study were time to disease control, partial remission (PR) and complete remission (CR). Results There was no significant difference in time to achieve PR between the two groups (147 vs. 135 days, P = 0·65). However, group 2 demonstrated better outcomes than group 1 in time to CR (443 vs. 149 days, P = 0·06) and relapse rate (0% vs. 67%, P < 0·01). Conclusions We conclude that three or more infusions of rituximab are more effective than two infusions for the treatment of pemphigus.

Original languageEnglish
Pages (from-to)646-651
Number of pages6
JournalBritish Journal of Dermatology
Volume165
Issue number3
DOIs
Publication statusPublished - 2011 Sep 1

Fingerprint

Pemphigus
Retrospective Studies
Therapeutics
CD20 Antigens
Immunosuppressive Agents
Rituximab
Anti-Idiotypic Antibodies
B-Lymphocytes
Monoclonal Antibodies
Recurrence

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

@article{83c0e27943d94996be94bbfaa129872c,
title = "Clinical efficacy of different doses of rituximab in the treatment of pemphigus: A retrospective study of 27 patients",
abstract = "Summary Background The treatment of pemphigus is still challenging and some patients with pemphigus are unresponsive to conventional immunosuppressive treatments. Rituximab, a chimeric monoclonal anti-CD20 antibody, binds to the CD20 antigen on the surface of B cells and has been reported to be effective for the treatment of recalcitrant pemphigus. Objective To compare the efficacy of different doses of rituximab in patients with pemphigus who were unresponsive to conventional therapies. Methods Twenty-seven patients with pemphigus who received different doses of rituximab (375 mg m -2 per infusion weekly) were analysed retrospectively. We divided the patients into two groups: group 1 (n = 12) received two infusions of rituximab and group 2 (n = 15) received three or more infusions of rituximab at 1-week intervals. The number of infusions was determined by the choice of each patient. The endpoints of the study were time to disease control, partial remission (PR) and complete remission (CR). Results There was no significant difference in time to achieve PR between the two groups (147 vs. 135 days, P = 0·65). However, group 2 demonstrated better outcomes than group 1 in time to CR (443 vs. 149 days, P = 0·06) and relapse rate (0{\%} vs. 67{\%}, P < 0·01). Conclusions We conclude that three or more infusions of rituximab are more effective than two infusions for the treatment of pemphigus.",
author = "Kim, {J. H.} and Kim, {Y. H.} and Kim, {M. R.} and SooChan Kim",
year = "2011",
month = "9",
day = "1",
doi = "10.1111/j.1365-2133.2011.10411.x",
language = "English",
volume = "165",
pages = "646--651",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "3",

}

Clinical efficacy of different doses of rituximab in the treatment of pemphigus : A retrospective study of 27 patients. / Kim, J. H.; Kim, Y. H.; Kim, M. R.; Kim, SooChan.

In: British Journal of Dermatology, Vol. 165, No. 3, 01.09.2011, p. 646-651.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical efficacy of different doses of rituximab in the treatment of pemphigus

T2 - A retrospective study of 27 patients

AU - Kim, J. H.

AU - Kim, Y. H.

AU - Kim, M. R.

AU - Kim, SooChan

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Summary Background The treatment of pemphigus is still challenging and some patients with pemphigus are unresponsive to conventional immunosuppressive treatments. Rituximab, a chimeric monoclonal anti-CD20 antibody, binds to the CD20 antigen on the surface of B cells and has been reported to be effective for the treatment of recalcitrant pemphigus. Objective To compare the efficacy of different doses of rituximab in patients with pemphigus who were unresponsive to conventional therapies. Methods Twenty-seven patients with pemphigus who received different doses of rituximab (375 mg m -2 per infusion weekly) were analysed retrospectively. We divided the patients into two groups: group 1 (n = 12) received two infusions of rituximab and group 2 (n = 15) received three or more infusions of rituximab at 1-week intervals. The number of infusions was determined by the choice of each patient. The endpoints of the study were time to disease control, partial remission (PR) and complete remission (CR). Results There was no significant difference in time to achieve PR between the two groups (147 vs. 135 days, P = 0·65). However, group 2 demonstrated better outcomes than group 1 in time to CR (443 vs. 149 days, P = 0·06) and relapse rate (0% vs. 67%, P < 0·01). Conclusions We conclude that three or more infusions of rituximab are more effective than two infusions for the treatment of pemphigus.

AB - Summary Background The treatment of pemphigus is still challenging and some patients with pemphigus are unresponsive to conventional immunosuppressive treatments. Rituximab, a chimeric monoclonal anti-CD20 antibody, binds to the CD20 antigen on the surface of B cells and has been reported to be effective for the treatment of recalcitrant pemphigus. Objective To compare the efficacy of different doses of rituximab in patients with pemphigus who were unresponsive to conventional therapies. Methods Twenty-seven patients with pemphigus who received different doses of rituximab (375 mg m -2 per infusion weekly) were analysed retrospectively. We divided the patients into two groups: group 1 (n = 12) received two infusions of rituximab and group 2 (n = 15) received three or more infusions of rituximab at 1-week intervals. The number of infusions was determined by the choice of each patient. The endpoints of the study were time to disease control, partial remission (PR) and complete remission (CR). Results There was no significant difference in time to achieve PR between the two groups (147 vs. 135 days, P = 0·65). However, group 2 demonstrated better outcomes than group 1 in time to CR (443 vs. 149 days, P = 0·06) and relapse rate (0% vs. 67%, P < 0·01). Conclusions We conclude that three or more infusions of rituximab are more effective than two infusions for the treatment of pemphigus.

UR - http://www.scopus.com/inward/record.url?scp=80052252494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052252494&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2133.2011.10411.x

DO - 10.1111/j.1365-2133.2011.10411.x

M3 - Article

VL - 165

SP - 646

EP - 651

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 3

ER -